Clinical Trial Update: Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating rifaximin to prevent postoperative recurrence in Crohn's disease; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• XIFAXAN (rifaximin)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Crohn Disease | Phase 3 | Status: UNKNOWN